Three drugmakers each have four blood pressure drugs in short supply after some were recalled in 2022 because of the presence of nitrosamine, which the FDA has labeled as a "probable human carcinogen."
Lupin Pharmaceuticals discontinued some quinapril tablets and recalled others in late December 2022, according to the American Society of Health-System Pharmacists. Pfizer and Solco Healthcare U.S. have their quinapril products on back order and allocation, respectively, and neither could estimate a resupply date.
Pfizer also reported a recall last April for 11 lots of its quinapril oral tablets, marketed as Accupril, but the drugmaker's current shortage is because of a manufacturing delay, according to the ASHP.